EU-India Pharmaceutical Trade: Opportunities and Challenges in Biopharmaceutical Innovation
A European Federation of Pharmaceutical Industries and Associations (EFPIA) statement has welcomed the European Union’s progress in concluding negotiations for a Free Trade Agreement with India. EU-India Pharmaceutical Trade relations have gained strategic importance amid geopolitical uncertainty and supply chain pressures. The statement highlights that enhanced collaboration in the life sciences sector could significantly advance innovation and improve patient access to medicines.
Tariff Wins Mask Unresolved Barriers
While the agreement includes positive elements such as the elimination of tariffs on most EU pharmaceutical exports, EFPIA stresses that several critical areas require continued high-level engagement.
A central insight from the EFPIA position is the need for robust protection of regulatory data. This is identified as a foundational requirement for a strong biopharmaceutical innovation ecosystem in India. Effective implementation of a meaningful regulatory data protection system remains essential to incentivize investment in innovative therapies.
The absence of provisions addressing government procurement within the FTA is noted as a significant gap. This omission leaves European companies exposed to localisation policies introduced in India in recent years, which continue to create substantial market access challenges.
Implications for Global Market Access
EFPIA’s commitment to continued dialogue on EU-India Pharmaceutical Trade signals an opportunity for health economists and market access professionals to incorporate evolving trade policy dynamics into their strategic planning.
